Ginkgo Bioworks Holdings (DNA) EBIT (2020 - 2026)

Ginkgo Bioworks Holdings has reported EBIT for 7 years, with the latest figure at -$71.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 11.85% year-over-year to -$71.4 million; the trailing twelve-month figure through Mar 2026 stood at -$297.7 million (up 35.67% YoY), and the FY2025 full-year result was -$315.3 million, up 43.68% from the prior year.
• EBIT for Q1 2026 stood at -$71.4 million, down from -$70.8 million in the prior quarter.
• The five-year high for EBIT was -$55.2 million in Q3 2024, with the low at -$675.4 million in Q1 2022.
• Historically, EBIT has averaged -$236.0 million across 5 years, with a median of -$178.1 million in 2023.
• The largest YoY upside for EBIT was 86.3% in 2022 against a maximum downside of 2355.53% in 2022.
• Ginkgo Bioworks Holdings' EBIT stood at -$230.9 million in 2022, then increased by 22.85% to -$178.1 million in 2023, then soared by 41.83% to -$103.6 million in 2024, then soared by 31.71% to -$70.8 million in 2025, then slipped by 0.88% to -$71.4 million in 2026.
• The last three EBIT figures came in at -$71.4 million (Q1 2026), -$70.8 million (Q4 2025), and -$90.0 million (Q3 2025), per Business Quant data.